Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. For 12 years, Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Feb 13, 2020 · One of the central figures behind that medical success story is Dennis J. Slamon, MD, PhD, a professor and chief of hematology/oncology at the David Geffen School of Medicine at the University of California at Los Angeles (UCLA). Slamon was born and reared in New Castle, a city with a storied past of boom and bust, situated on the banks of the Shenango River in Lawrence County, Pennsylvania. Mar 20, 2025 · From groundbreaking research to life-saving impact, Dr. DennisSlamon joins NFCR CEO Dr. Sujuan Ba to discuss the pioneering work and collaboration that led to the eventual FDA approval of Herceptin, and what’s next in cancer research. Who invented Herceptin?One of the central figures behind that medical success story is Dennis J. Slamon, MD, PhD, a professor and chief of hematology/oncology at the David Geffen School of Medicine at the University of California at Los Angeles (UCLA). Slamon received a Lasker-DeBakey Clinical Medical Research Award in September 2019.What is Herceptin & how does it work?For 12 years, Dr. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients.Dr. Slamon, M.D., Ph.D., a UCLA oncologist and researcher, transformed breast cancer treatment through his pioneering identification of the HER2/neu oncogene, amplified in roughly a quarter to a third of breast cancers. Feb 13, 2020 · One of the central figures behind that medical success story is Dennis J.
